Laboratory Co. of America Holdings (NYSE:LH – Get Free Report) EVP Der Vaart Sandra D. Van sold 259 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $222.06, for a total transaction of $57,513.54. Following the transaction, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Laboratory Co. of America Price Performance
Laboratory Co. of America stock opened at $222.59 on Monday. The firm has a 50-day moving average price of $223.49 and a 200-day moving average price of $213.20. The firm has a market capitalization of $18.90 billion, a PE ratio of 29.76 and a beta of 1.04. The company has a current ratio of 1.36, a quick ratio of 1.20 and a debt-to-equity ratio of 0.57. Laboratory Co. of America Holdings has a 12-month low of $174.20 and a 12-month high of $234.09.
Laboratory Co. of America Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 13th. Investors of record on Tuesday, February 27th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $2.88 dividend on an annualized basis and a yield of 1.29%. Laboratory Co. of America’s payout ratio is 38.50%.
Institutional Investors Weigh In On Laboratory Co. of America
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on LH shares. Mizuho dropped their target price on shares of Laboratory Co. of America from $257.00 to $230.00 and set a “buy” rating for the company in a research report on Tuesday, October 31st. JPMorgan Chase & Co. upped their target price on shares of Laboratory Co. of America from $259.00 to $261.00 and gave the stock an “overweight” rating in a research report on Friday, November 17th. TheStreet upgraded shares of Laboratory Co. of America from a “c+” rating to a “b-” rating in a research report on Thursday, January 18th. Evercore ISI assumed coverage on shares of Laboratory Co. of America in a research report on Friday. They set an “in-line” rating and a $240.00 price objective for the company. Finally, Barclays assumed coverage on shares of Laboratory Co. of America in a research report on Wednesday, January 3rd. They set an “equal weight” rating and a $222.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.86.
Laboratory Co. of America Company Profile
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.
- Five stocks we like better than Laboratory Co. of America
- Retail Stocks Investing, Explained
- MarketBeat Week in Review – 2/5 – 2/9
- How to Use the MarketBeat Stock Split Calculator
- Cloudflare results spark analysts reset: 25% upside ahead
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.